Earnings results for ITUS (NYSE:ANIX)
Anixa Biosciences, Inc. is estimated to report earnings on 09/04/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.11.
ITUS last issued its quarterly earnings results on June 9th, 2020. The reported ($0.12) earnings per share (EPS) for the quarter. ITUS has generated $0.00 earnings per share over the last year. ITUS has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, September 4th, 2020 based off prior year’s report dates.
Analyst Opinion on ITUS (NYSE:ANIX)
2 Wall Street analysts have issued ratings and price targets for ITUS in the last 12 months. Their average twelve-month price target is $8.25, predicting that the stock has a possible upside of 350.82%. The high price target for ANIX is $8.50 and the low price target for ANIX is $8.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
ITUS has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $8.25, ITUS has a forecasted upside of 350.8% from its current price of $1.83. ITUS has received no research coverage in the past 90 days.
Dividend Strength: ITUS (NYSE:ANIX)
ITUS does not currently pay a dividend. ITUS does not have a long track record of dividend growth.
Insiders buying/selling: ITUS (NYSE:ANIX)
In the past three months, ITUS insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $113,645.00 in company stock and sold $0.00 in company stock.
Earnings and Valuation of ITUS (NYSE:ANIX
More latest stories: here